1072448-08-8

Basic information

• Product Name: Methyl 3-amino-5-bromopicolinate
• Synonyms: Methyl 3-amino-5-bromopicolinate;3-AMino-5-broMopyridin-2-carboxylic acid Methyl ester;Methyl 3-aMino-5-broMopyridine-2-carboxylate
• CAS NO: 1072448-08-8
• Molecular Formula: C₇H₇BrN₂O₂
• Molecular Weight: 231.04668
• Mol File: 1072448-08-8.mol

Chemical Properties

• Boiling Point: 371.9±37.0 °C(Predicted)
• Appearance: /
• Density: 1.662±0.06 g/cm3(Predicted)
• PKA: 0.30±0.10(Predicted)
• CAS DataBase Reference: Methyl 3-amino-5-bromopicolinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-amino-5-bromopicolinate(1072448-08-8)
• EPA Substance Registry System: Methyl 3-amino-5-bromopicolinate(1072448-08-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1072448-08-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-amino-5-bromopicolinate is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs. Its bromine and amino functional groups provide versatility in chemical reactions, facilitating the creation of diverse bioactive molecules.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 3-amino-5-bromopicolinate is utilized as a building block in the synthesis of agrochemicals, potentially enhancing the effectiveness of pesticides or other agricultural chemicals by introducing novel chemical properties.
Used in Medicinal Chemistry Research:
Methyl 3-amino-5-bromopicolinate serves as a valuable compound in medicinal chemistry research, where its unique structure and functional groups are explored for their potential to yield new insights into drug discovery and the design of therapeutic agents.
Used in Organic Synthesis:
As a versatile organic synthesis compound, Methyl 3-amino-5-bromopicolinate is employed in various chemical reactions to produce a range of organic compounds, including those with potential applications in material science, chemical engineering, and other related fields.

Upstream product

• 67-56-1 methanol 
• 870997-85-6 3-amino-5-bromo-pyridine-2-carboxylic acid 
• 1211538-72-5 methyl 5-bromo-3-fluoro-pyridine-2-carboxylate 
• 74-88-4 methyl iodide 

Downstream Products

• 863443-05-4 3-amino-5-(4-fluoro-benzyl)-pyridine-2-carboxylic acid methyl ester 

Relevant articles and documents

Pyrazole derivative for FGFR inhibitor and preparation method of pyrazole derivative

The invention provides a pyrazole derivative for an FGFR inhibitor and a preparation method of the pyrazole derivative. The invention specifically relates to an amide pyrazole compound serving as an FGFR irreversible inhibitor, and a preparation method and application thereof. The present invention provides a compound as shown in Formula I, or a pharmaceutically acceptable salt, or solvate, isotope substitute, prodrug, or metabolite thereof. The compound as shown in general formula I have FGFR inhibitory activity, and is capable of preventing or treating disorders associated with FGFR activityor expression, preferably such as cancer.

Identification and preliminary structure-activity relationship studies of 1,5-dihydrobenzo[e][1,4]oxazepin-2(3h)-ones that induce differentiation of acute myeloid leukemia cells in vitro

Acute myeloid leukemia (AML) is the most aggressive type of blood cancer, and there is a continued need for new treatments that are well tolerated and improve long-term survival rates in patients. Induction of differentiation has emerged as a promising alternative to conventional cy-totoxic chemotherapy, but known agents lack efficacy in genetically distinct patient populations. Previously, we established a phenotypic screen to identify small molecules that could stimulate differentiation in a range of AML cell lines. Utilising this strategy, a 1,5-dihydrobenzo[e][1,4]oxazepin-2(3H)-one hit compound was identified. Herein, we report the hit validation in vitro, structure-ac-tivity relationship (SAR) studies and the pharmacokinetic profiles for selected compounds.

SUBSTITUTED PYRIDINES AND METHOD OF USE

The invention discloses compounds of Formula (I) wherein X, R1, R2, and R3 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.